Search Results - "CHOUAKI, Nadia"

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer by Senan, Suresh, Brade, Anthony, Wang, Lu-Hua, Vansteenkiste, Johan, Dakhil, Shaker, Biesma, Bonne, Martinez Aguillo, Maite, Aerts, Joachim, Govindan, Ramaswamy, Rubio-Viqueira, Belén, Lewanski, Conrad, Gandara, David, Choy, Hak, Mok, Tony, Hossain, Anwar, Iscoe, Neill, Treat, Joseph, Koustenis, Andrew, San Antonio, Bélen, Chouaki, Nadia, Vokes, Everett

“…The phase III PROCLAIM study evaluated overall survival (OS) of concurrent pemetrexed-cisplatin and thoracic radiation therapy (TRT) followed by consolidation…”
Get full text

PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer by PAZ-ARES, Luis G, DE MARINIS, Filippo, CORRAL, Jesús, MELEMED, Symantha, JOHN, William, CHOUAKI, Nadia, ZIMMERMANN, Annamaria H, VISSEREN-GRUL, Carla, GRIDELLI, Cesare, DEDIU, Mircea, THOMAS, Michael, PUJOL, Jean-Louis, BIDOLI, Paolo, MOLINIER, Olivier, TARINI PRASAD SAHOO, LAACK, Eckart, RECK, Martin

“…In the phase III PARAMOUNT trial, pemetrexed continuation maintenance therapy reduced the risk of disease progression versus placebo (hazard ratio [HR], 0.62;…”
Get full text

Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial by Paz-Ares, Luis, Dr, de Marinis, Filippo, MD, Dediu, Mircea, MD, Thomas, Michael, Prof, Pujol, Jean-Louis, Prof, Bidoli, Paolo, MD, Molinier, Olivier, MD, Sahoo, Tarini Prasad, MD, Laack, Eckart, Prof, Reck, Martin, MD, Corral, Jesús, MD, Melemed, Symantha, PhD, John, William, MD, Chouaki, Nadia, MD, Zimmermann, Annamaria H, MS, Visseren-Grul, Carla, MD, Gridelli, Cesare, MD

“…Summary Background Patients with advanced non-squamous non-small-cell lung cancer (NSCLC) benefit from pemetrexed maintenance therapy after induction therapy…”
Get full text

Safety and efficacy of abemaciclib plus endocrine therapy in older patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: an age-specific subgroup analysis of MONARCH 2 and 3 trials by Goetz, Matthew P., Okera, Meena, Wildiers, Hans, Campone, Mario, Grischke, Eva-Maria, Manso, Luis, André, Valérie A. M., Chouaki, Nadia, San Antonio, Belén, Toi, Masakazu, Sledge, George W.

“…Purpose Abemaciclib in combination with endocrine therapy (ET) has demonstrated significant efficacy benefits in HR+ , HER2− advanced breast cancer patients in…”
Get full text

Safety, resource use, and quality of life in paramount: a phase III study of maintenance pemetrexed versus placebo after induction pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer by Gridelli, Cesare, de Marinis, Filippo, Pujol, Jean-Louis, Reck, Martin, Ramlau, Rodryg, Parente, Barbara, Pieters, Thierry, Middleton, Gary, Corral, Jesus, Winfree, Katherine, Melemed, Symantha, Zimmermann, Anna, John, William, Beyrer, Julie, Chouaki, Nadia, Visseren-Grul, Carla, Paz-Ares, Luis G

“…In a phase III, randomized, double-blind study (PARAMOUNT), maintenance pemetrexed demonstrated significant benefit in advanced non-small-cell lung cancer…”
Get more information

Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC) by Senan, Suresh, Brade, Anthony M., Wang, Luhua, Vansteenkiste, Johan F., Dakhil, Shaker R., Biesma, Bonne, Martinez Aguillo, Maite, Aerts, Joachim, Govindan, Ramaswamy, Rubio-Viqueira, Belén, Lewanski, Conrad R., Gandara, David R., Choy, Hak, Mok, Tony, Hossain, Anwar, Iscoe, Neill Allan, Treat, Joseph, Koustenis, Andrew G., Chouaki, Nadia, Vokes, Everett E.

“…Abstract only…”
Get full text

A phase II single-arm study of induction chemotherapy with cisplatin and gemcitabine followed by concurrent cisplatin and gemcitabine with thoracic radiation for unresectable locally advanced non-small cell lung cancer by Driesen, Peter, Lambrechts, Marc, Kraaij, Kees, Soldatenkova, Victoria, Chouaki, Nadia, Colinet, Benoit

“…Objectives: The aim of this study was to evaluate the efficacy and tolerability of the combination of cisplatin–gemcitabine with concurrent thoracic…”
Get full text

Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial by Brade, Anthony M., Wenz, Frederik, Koppe, Friederike, Lievens, Yolande, San Antonio, Belen, Iscoe, Neill A., Hossain, Anwar, Chouaki, Nadia, Senan, Suresh

“…Chemoradiation therapy trials of different tumors, including lung cancer, have shown a correlation between protocol deviations and adverse outcomes. Radiation…”
Get full text

Identification of Patients with Early HR+ HER2- Breast Cancer at High Risk of Recurrence by Fasching, Peter A, Kreipe, Hans, Del Mastro, Lucia, Ciruelos, Eva, Freyer, Gilles, Korfel, Agnieszka, Chouaki, Nadia, Stoffregen, Clemens, Sapunar, Francisco, Cameron, David

“…Breast cancer incidence has increased in the last two decades and, simultaneously, survival has improved due to earlier detection and improved treatment…”
Get full text

Final efficacy and safety results of pemetrexed continuation maintenance therapy in the elderly from the PARAMOUNT phase III study by Gridelli, Cesare, de Marinis, Filippo, Thomas, Michael, Prabhash, Kumar, El Kouri, Claude, Blackhall, Fiona, Bustin, Frederique, Pujol, Jean-Louis, John, William J, San Antonio, Belen, Zimmermann, Annamaria, Chouaki, Nadia, Visseren-Grul, Carla, Paz-Ares, Luis G

“…The PARAMOUNT Phase III trial showed that maintenance pemetrexed after pemetrexed plus cisplatin induction was well tolerated and effective for patients with…”
Get more information

Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC) by Garrido, Pilar, Engel-Riedel, Walburga, Serke, Monika, Giraud, Philippe, Ricardi, Umberto, Vallejo, Carmen, Visseren-Grul, Carla, Ameryckx, Sophie, Soldatenkova, Victoria, Chouaki, Nadia, Novello, Silvia

“…Highlights • This was a Phase II study in patients with locally advanced non-squamous NSCLC. • It assessed Pem-Cis induction CT followed by full-dose Pem-Cis…”
Get full text

Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer by Govindan, Ramaswamy, Senan, Suresh, Dickgreber, Nicolas, Provencio, Mariano, Wu, Yi-Long, Syrigos, Konstantinos, Parente, Barbara, Wilson, Michele, Ziemiecki, Ryan, Chouaki, Nadia, Hossain, Anwar, San Antonio, Belén, Winfree, Katherine, Vokes, Everett E.

“…Objective: To analyze patient-reported swallowing difficulties, healthcare resource utilization and associated costs during the PROCLAIM study. Methods:…”
Get full text

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer by Pujol, Jean-Louis, Paz-Ares, Luis, de Marinis, Filippo, Dediu, Mircea, Thomas, Michael, Bidoli, Paolo, Corral, Jesus, San Antonio, Belen, Chouaki, Nadia, John, William, Zimmermann, Annamaria, Visseren-Grul, Carla, Gridelli, Cesare

“…Micro-Abstract Updated long-term, low-grade (grade 1/2) safety and quality of life (QoL) results from the randomized, double-blind maintenance phase of the…”
Get full text

Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer by Middleton, Gary, Gridelli, Cesare, De Marinis, Filippo, Pujol, Jean-Louis, Reck, Martin, Ramlau, Rodryg, Parente, Barbara, Pieters, Thierry, Visseren-Grul, Carla M, San Antonio, Bélen, John, William J, Zimmermann, Annamaria Hayden, Chouaki, Nadia, Paz-Ares, Luis

“…To assess the effect of long-term pemetrexed maintenance therapy on patients' renal function. In the PARAMOUNT phase III trial (NCT 00789373), pemetrexed was…”
Get full text

The Effect of Necitumumab in Combination with Gemcitabine plus Cisplatin on Tolerability and on Quality of Life: Results from the Phase 3 SQUIRE Trial by Reck, Martin, Socinski, Mark A, Luft, Alexander, Szczęsna, Aleksandra, Dediu, Mircea, Ramlau, Rodryg, Losonczy, György, Molinier, Olivier, Schumann, Christian, Gralla, Richard J, Bonomi, Philip, Brown, Jacqueline, Soldatenkova, Victoria, Chouaki, Nadia, Obasaju, Coleman, Peterson, Patrick, Thatcher, Nick

“…Necitumumab, a second-generation, recombinant human immunoglobulin G1 epidermal growth factor receptor antibody in the phase 3 SQUIRE trial (NCT00981058),…”
Get more information

Pemetrexed and carboplatin, an active option in first-line treatment of elderly patients with advanced non-small cell lung cancer (NSCLC): A phase II trial by Gervais, Radj, Robinet, Gilles, Clément-Duchêne, Christelle, Denis, Fabrice, Kouri, Claude El, Martin, Philippe, Chouaki, Nadia, Bourayou, Nawel, Morère, Jean-François

“…Abstract The synergistic activity of pemetrexed with platinum agents in non-small cell lung cancer (NSCLC) and the renal safety of carboplatin suggest a…”
Get full text

Final overall survival (OS) results from a phase II study of pemetrexed (Pem) and cisplatin (Cis) with concurrent thoracic radiation (RT) after Pem-Cis induction in patients with unresectable locally advanced (LA) nonsquamous non-small cell lung cancer (NS-NSCLC) by Novello, Silvia, Engel-Riedel, Walburga, Serke, Monika, Giraud, Philippe, Visseren-Grul, Carla, Ameryckx, Sophie, Soldatenkova, Victoria, Chouaki, Nadia, Garrido, Pilar

“…Abstract only…”
Get full text

Subgroup analyses by performance status (PS) in the phase III SQUIRE study: First-line necitumumab (N) plus gemcitabine-cisplatin (GC) vs. GC in squamous non-small cell lung cancer (NSCLC) by Socinski, Mark A., Luft, Alexander, Szczesna, Aleksandra, Szafranski, Wojciech, Galiulin, Rinat, Bálint, Beatrix, Park, Keunchil, Reck, Martin, Depenbrock, Henrik, Nanda, Shivani, Chouaki, Nadia, Thatcher, Nick

“…Abstract only…”
Get full text

Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC) by Govindan, Ramaswamy, Senan, Suresh, Dickgreber, Nicolas J., Provencio, Mariano, Wu, Yi-Long, Syrigos, Konstantinos N., Parente, Bárbara, Chouaki, Nadia, Hossain, Anwar, San Antonio, Belén, Winfree, Katherine B., Vokes, Everett E.

“…Abstract only…”
Get full text

Phase I study of pemetrexed and cisplatin with concurrent high-dose thoracic radiation after induction chemotherapy in patients with unresectable locally advanced non-small cell lung cancer by Mornex, Françoise, Peignaux, Karine, Germain, Thierry, Wautot, Virginie, Chouaki, Nadia, Bourayou, Nawel, Tourani, Jean-Marc

“…Abstract Purpose This is a phase I, escalating-dose trial targeting exclusively patients with non-small cell lung cancer (NSCLC), investigating pemetrexed and…”
Get full text